75 results
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
but for injury, ill health, disability, pregnancy, childbirth, maternity, paternity or parental leave, reasonable holiday entitlement or not being … Holder holding a Nominal-Cost Option ceases to be Connected for one of the following reasons:
death;
disability, injury or ill health (evidenced
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
the employee would have been required to so spend but for injury, ill health, disability, pregnancy, childbirth, maternity, paternity or parental leave … ceases to be Connected for one of the following reasons:
death;
disability, injury or ill health (evidenced to the satisfaction of the Board
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
or injury or product liability claim resulting from (i) the conduct of the Active Trials from and after the applicable Active Trial Transfer Date … death or injury or product liability claim resulting from (i) the conduct of the ZENYTH Trial and the Completed Trials, (ii) the conduct of the
Active
424B5
ADAP
Adaptimmune Therapeutics Plc
28 Apr 22
Prospectus supplement for primary offering
8:09am
patients into clinical trials;
claims for personal injury or death arising from the use of our cell therapies;
our ability to attract and retain
S-3ASR
wpzicrz06
10 Aug 20
Automatic shelf registration
5:01pm
424B5
gr8dxc6
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
6t6kdp48
1 Jun 20
Prospectus supplement for primary offering
6:06am
424B5
xejf b9y8reu
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
2aj1qrv8s2p 3r
21 Jan 20
Prospectus supplement for primary offering
5:21pm